Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial

Objective: To assess the efficacy and safety of ultra-low dose 0.005% estriol vaginal gel in women with breast cancer receiving nonsteroidal aromatase inhibitors (NSAIs) and experiencing treatment-related vulvovaginal symptoms and signs. Methods: Women with hormone receptor-positive early breast cancer receiving NSAIs were randomized to either estriol vaginal gel or placebo for 12 weeks. Vaginal maturation, vaginal pH, and total and individual scores of symptoms and signs of vulvovaginal atrophy were assessed at baseline and at weeks 3 and 12; sexual functioning was also evaluated using the Female Sexual Functioning Index (FSFI) questionnaire, as well as circulating estrogens, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Results: Sixty-one women with a mean age of 59 years were included: 50 received 0.005% estriol vaginal gel and 11 received placebo. Active treatment significantly improved maturation value and pH, vaginal dryness and global scores of symptoms and signs. Active treatment also increased the total FSFI score and all the FSFI domains, with the exception of pain. Small oscillations were observed in FSH and LH, which remained within the postmenopausal range. Estriol levels increased initially and normalized by week 12, and estradiol and estrone remained mostly undetectable throughout the study. Conclusions: Ultra-low dose 0.005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy. These results, together with minimal oscillations in hormonal levels throughout the treatment, support the use of ultra-low dose 0.005% estriol vaginal gel as a treatment option for vulvovaginal atrophy in women with breast cancer receiving NSAIs with an indication for treatment with vaginal estrogens

Pengaruh Content Marketing Dan Customer Value Terhadap Keputusan Pembelian Pada Produk Kosmetik Ms Glow di Kelurahan Rimba Sekampung Kecamatan Dumai Kota

Produk kecantikan saat ini menjadi suatu kebutuhan bagi konsumen, terutama konsumen wanita. Fenomena ini membuka peluang bagi industri kecantikan terutama bagi industri MS Glow untuk menghasilkan produk yang berkualitas. Penelitian ini dilakukan di Kelurahan Rimba Sekampung Kecamatan Dumai Kota. Adapun tujuan penelitian ini adalah untuk mengetahui pengaruh Content Marketing dan Customer Value terhadap keputusan pembelian pada produk kosmetik MS Glow di Kelurahan Rimba Sekampung Kecamatan Dumai Kota. Jumlah sampel dalam penelitian ini adalah 100 responden dengan menggunakan metode Purposive Sampling dengan kriteria berusia 17-30 tahun dan pernah membeli produk kosmetik MS Glow. Metode dalam penelitian ini adalah deskriptif kuantitatif dengan regresi linier berganda dan menggunakan program SPSS versi 17,2021. Dari hasil Uji t variabel Content Marketing dan Customer Value berpengaruh signifikan terhadap keputusan pembelian. Dengan menggunakan Uji F variabel Content Marketing dan Customer Value berpengaruh signifikan secara simultan terhadap keputusan pembelian. Sedangkan hasil koefesien determinasi sebesar 40,8% dan sisanya 59,2% dipengaruhi oleh variabel lain yang tidak diteliti oleh peneliti

Arterial hypertension

Arterial hypertension is the most important contributor to the global burden of disease; however, disease control remains poor. Although the diagnosis of hypertension is still based on office blood pressure, confirmation with out-of-office blood pressure measurements (ie, ambulatory or home monitoring) is strongly recommended. The definition of hypertension differs throughout various guidelines, but the indications for antihypertensive therapy are relatively similar. Lifestyle adaptation is absolutely key in non-pharmacological treatment. Pharmacologically, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, calcium channel blockers, and diuretics are the first-line agents, with advice for the use of single-pill combination therapy by most guidelines. As a fourth-line agent, spironolactone should be considered. The rapidly evolving field of device-based therapy, especially renal denervation, will further broaden therapeutic options. Despite being a largely controllable condition, the actual rates of awareness, treatment, and control of hypertension are disappointingly low. Further improvements throughout the process of patient screening, diagnosis, treatment, and follow-up need to be urgently addressed